Merck granted FDA approval for Keytruda as adjuvant therapy in renal cell carcinoma
18 November 2021 - 11:03PM
Seeking Alpha
To read the full story on Seeking Alpha, click
here.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024